[Treatment of osteoporosis with antiresorptive drugs].
Vestergaard
Peter
P
Arhus Universitetshospital, Arhus Sygehus, Medicinsk Endokrinologisk Afdeling C. p-vest@post4.tele.dk
Mosekilde
Leif
L
Brixen
Kim
K
D015519:Bone Density / Q000187:drug effects; D001862:Bone Resorption / Q000188:drug therapy*; D002116:Calcitonin / Q000008:administration & dosage; D002118:Calcium / Q000008:administration & dosage; D002762:Cholecalciferol / Q000008:administration & dosage; D004164:Diphosphonates / Q000008:administration & dosage; D004958:Estradiol / Q000008:administration & dosage; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy* / Q000517:prevention & control; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000517:prevention & control; D011374:Progesterone / Q000008:administration & dosage; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage; D014807:Vitamin D / Q000008:administration & dosage
D004164:Diphosphonates; D004966:Estrogens, Conjugated (USP); D020845:Selective Estrogen Receptor Modulators; D014807:Vitamin D; D002762:Cholecalciferol; D020849:Raloxifene Hydrochloride; D011374:Progesterone; D004958:Estradiol; D002116:Calcitonin; D002118:Calcium